» Articles » PMID: 29357895

Clinical Significance of Peripheral Circulating Tumor Cell Counts in Colorectal Polyps and Non-metastatic Colorectal Cancer

Overview
Publisher Biomed Central
Date 2018 Jan 24
PMID 29357895
Citations 11
Authors
Affiliations
Soon will be listed here.
Abstract

Background: The presence of peripheral circulating tumor cells indicates the possible existence of a tumor in vivo; however, low numbers of circulating tumor cells (CTCs) can be detected in peripheral blood of healthy individuals as well as patients with benign tumors. It is not known whether peripheral CTC counts differ between patients with benign colorectal disease and those with colorectal cancer.

Methods: Comparative analysis of preoperative peripheral circulating tumor cells counts was completed in patients with benign colorectal disease (colorectal polyps) and non-metastatic cancer of the colon and rectum.

Results: The results of this analysis showed that patients with colorectal cancer had higher CTC counts than patients with colorectal polyps (3.47 ± 0.32/3.2 ml vs 1.49 ± 0.2/3.2 ml, P < 0.001). Colorectal cancer patients with tumors of the sigmoid colon displayed the highest CTC counts (4.87 ± 0.95/3.2 ml), followed by those with tumors of the rectum (3.73 ± 0.54/3.2 ml), ascending colon (3.5 ± 0.63/3.2 ml), transverse colon (2.4 ± 0.68/3.2 ml), and descending colon (2.08 ± 0.46/3.2 ml). Colorectal polyp patients with polyps in the rectum showed the highest CTC counts (2.2 ± 0.77/3.2 ml), followed by those with polyps in the ascending colon (1.82 ± 0.54/3.2 ml), sigmoid colon (1.38 ± 0.25/3.2 ml), transverse colon (0.75 ± 0.25/3.2 ml), and descending colon (0.33 ± 0.21/3.2 ml). The differences in CTC counts suggest that anatomical location of colorectal tumors may affect blood vessel metastasis. Meanwhile, patients with moderately differentiated and poorly differentiated tumors displayed higher peripheral blood CTC counts compared to those with well-differentiated tumors (P < 0.001). This result suggests that the type of tissue differentiation of colorectal tumors may act as another factor that affects blood vessel metastasis.

Conclusions: Circulating tumor cells can be detected in the peripheral blood of colorectal cancer patients as well as patients with colorectal polyps. The differences in CTC counts suggest that anatomical location and the type of tissue differentiation of colorectal tumors may affect blood vessel metastasis.

Citing Articles

Immunolipid magnetic bead-based circulating tumor cell sorting: a novel approach for pathological staging of colorectal cancer.

Deng Q, Li W, Huang Y, Wang H, Zhou X, Guan Z Front Oncol. 2025; 14:1531972.

PMID: 39927117 PMC: 11803635. DOI: 10.3389/fonc.2024.1531972.


Liquid biopsy in cancer current: status, challenges and future prospects.

Ma L, Guo H, Zhao Y, Liu Z, Wang C, Bu J Signal Transduct Target Ther. 2024; 9(1):336.

PMID: 39617822 PMC: 11609310. DOI: 10.1038/s41392-024-02021-w.


How much do we know about the metastatic process?.

Rodriguez-Tirado C, Sosa M Clin Exp Metastasis. 2024; 41(4):275-299.

PMID: 38520475 PMC: 11374507. DOI: 10.1007/s10585-023-10248-0.


Exploring the Role of Circulating Cell-Free RNA in the Development of Colorectal Cancer.

Kan C, Pei X, Yeung M, Jin N, Ng S, Tsang H Int J Mol Sci. 2023; 24(13).

PMID: 37446204 PMC: 10341751. DOI: 10.3390/ijms241311026.


Liquid Biopsy and Artificial Intelligence as Tools to Detect Signatures of Colorectal Malignancies: A Modern Approach in Patient's Stratification.

Ginghina O, Hudita A, Zamfir M, Spanu A, Mardare M, Bondoc I Front Oncol. 2022; 12:856575.

PMID: 35356214 PMC: 8959149. DOI: 10.3389/fonc.2022.856575.


References
1.
Huang X, Gao P, Song Y, Sun J, Chen X, Zhao J . Relationship between circulating tumor cells and tumor response in colorectal cancer patients treated with chemotherapy: a meta-analysis. BMC Cancer. 2014; 14:976. PMC: 4302148. DOI: 10.1186/1471-2407-14-976. View

2.
de Bono J, Scher H, Montgomery R, Parker C, Miller M, Tissing H . Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res. 2008; 14(19):6302-9. DOI: 10.1158/1078-0432.CCR-08-0872. View

3.
Rack B, Schindlbeck C, Juckstock J, Andergassen U, Hepp P, Zwingers T . Circulating tumor cells predict survival in early average-to-high risk breast cancer patients. J Natl Cancer Inst. 2014; 106(5). PMC: 4112925. DOI: 10.1093/jnci/dju066. View

4.
Li S, Konstantinov S, Smits R, Peppelenbosch M . Bacterial Biofilms in Colorectal Cancer Initiation and Progression. Trends Mol Med. 2016; 23(1):18-30. DOI: 10.1016/j.molmed.2016.11.004. View

5.
Kasimir-Bauer S, Bittner A, Konig L, Reiter K, Keller T, Kimmig R . Does primary neoadjuvant systemic therapy eradicate minimal residual disease? Analysis of disseminated and circulating tumor cells before and after therapy. Breast Cancer Res. 2016; 18(1):20. PMC: 4751719. DOI: 10.1186/s13058-016-0679-3. View